# Eosinophilic Esophagitis FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/eosinophilic-esophagitis

> No upcoming FDA catalysts in eosinophilic Esophagitis; 6 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for eosinophilic Esophagitis?

No upcoming FDA catalysts in eosinophilic Esophagitis; 6 past events are recorded. SEC Form 8-K: "Topline results are anticipated in the fourth quarter 2026." [Calendar and source filings](https://sec-api.dev/indications/eosinophilic-esophagitis)

Source: SEC Form 8-K, accession 0001193125-26-278533, https://www.sec.gov/Archives/edgar/data/1783183/000119312526278533/d166684d8k.htm (retrieved 2026-11-12). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/indications/eosinophilic-esophagitis#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 4, 2025 | [Barzolvolimab primary completion](https://sec-api.dev/pdufa/barzolvolimab) | CLDX | Eosinophilic Esophagitis | completed | "NCT05774184 (A Study of CDX-0159 in Patients With Eosinophilic Esophagitis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-04 (ACTUAL); Lead Sponsor Celldex Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05774184)) |
| August 14, 2025 | [Cendakimab primary completion](https://sec-api.dev/pdufa/cendakimab) | BMY | Eosinophilic Esophagitis | completed | "NCT04991935 (Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-14 (ACTUAL); Lead Sponsor Celgene; Results First Posted 2026-04-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04991935)) |
| April 6, 2026 | [Cendakimab topline data readout](https://sec-api.dev/pdufa/cendakimab) | BMY | Eosinophilic Esophagitis | completed | "NCT04991935 (Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-14 (ACTUAL); Lead Sponsor Celgene; Results First Posted 2026-04-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04991935?tab=results)) |
| July 14, 2026 | [TEZSPIRE® (tezepelumab) primary completion](https://sec-api.dev/pdufa/tezepelumab) | AZN | Eosinophilic Esophagitis | completed | "NCT05583227 (Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-07-14 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05583227)) |
| September 11, 2026 | [VOQUEZNA® (vonoprazan) primary completion](https://sec-api.dev/pdufa/vonoprazan) | PHAT | Eosinophilic Esophagitis | completed | "NCT06851559 (A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-11 (ACTUAL); Lead Sponsor Phathom Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06851559)) |
| Q4 2026 | [VOQUEZNA® (vonoprazan) topline data readout](https://sec-api.dev/pdufa/vonoprazan) | PHAT | eosinophilic esophagitis | scheduled | "Topline results are anticipated in the fourth quarter 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1783183/000119312526278533/d166684d8k.htm)) |

## Drugs

- [Barzolvolimab](https://sec-api.dev/pdufa/barzolvolimab) (CLDX)
- [Cendakimab](https://sec-api.dev/pdufa/cendakimab) (BMY)
- [TEZSPIRE® (tezepelumab)](https://sec-api.dev/pdufa/tezepelumab) (AZN)
- [VOQUEZNA® (vonoprazan)](https://sec-api.dev/pdufa/vonoprazan) (PHAT)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/eosinophilic-esophagitis.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Eosinophilic Esophagitis FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/eosinophilic-esophagitis

```bibtex
@misc{secapidev_indications_eosinophilic_esophagitis_20261116,
  title        = {Eosinophilic Esophagitis FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/eosinophilic-esophagitis}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_eosinophilic_esophagitis_20261116","title":"Eosinophilic Esophagitis FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/eosinophilic-esophagitis","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
